Clinical Trials
142 trialsNCT05282459 2026-04-17
Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation
Stanford University
Phase 1/2 Completed
NCT06492304 2026-04-03
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies
CRISPR Therapeutics
Phase 1/2 Completed
NCT00576979 2026-03-24
Intensity-Modulated Radiation Therapy, Etoposide, and Cyclophosphamide Followed By Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
City of Hope Medical Center
Phase 1/2 Completed
NCT02158858 2025-10-08
A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies
Constellation Pharmaceuticals
Phase 1/2 Completed
NCT02356159 2025-09-30
Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT00410423 2025-04-30
Study of VELCADE® With Mitoxantrone and Etoposide for Leukemias
Thomas Jefferson University
Phase 1/2 Completed
NCT00081874 2025-04-27
RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT01063907 2024-04-25
A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
Kyowa Kirin Co., Ltd.
Phase 1/2 Completed
NCT02789254 2023-12-28
FLYSYN-101
Synimmune GmbH
Phase 1/2 Completed
NCT00924170 2023-11-14
Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT03903185 2023-08-22
Pharmacokinetics of Ledipasvir/Sofosbuvir in Hepatitis C Virus-Infected Children With Hematological Malignancy
Ain Shams University
Phase 1/2 Completed
NCT00516828 2023-08-04
Sorafenib and Low Dose Cytarabine in Older Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Canadian Cancer Trials Group
Phase 1/2 Completed
NCT00423514 2022-12-27
Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT01776723 2022-09-22
A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Completed
NCT01667133 2022-06-13
A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)
Takeda
Phase 1/2 Completed
NCT00416351 2022-05-17
Clofarabine in Treating Patients With T-Cell or Natural Killer-Cell Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT01994382 2022-04-05
Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL
Alexion Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT01893320 2022-02-09
Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00924326 2022-01-12
CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT02145403 2022-01-03
Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies
University of Michigan Rogel Cancer Center
Phase 1/2 Completed
NCT02328885 2021-12-08
Prophylactic Infusion of Donor Lymphocytes in Cord Blood Transplantation
Banc de Sang i Teixits
Phase 1/2 Completed
NCT02464657 2021-10-07
Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00546793 2021-08-16
Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL
Gilead Sciences
Phase 1/2 Completed
NCT04194086 2021-08-03
Population Pharmacokinetics and Safety of Oral Posaconazole in Children With Leukemia
Zhujiang Hospital
Phase 1/2 Completed
NCT00621244 2021-01-05
A Study of Oral LBH589 in Adult Patients With Advanced Hematological Malignancies
Novartis
Phase 1/2 Completed
NCT01474681 2020-12-30
Safety and Tolerability of HSC835 in Patients With Hematological Malignancies
Novartis
Phase 1/2 Completed
NCT00822770 2020-10-14
Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT02530476 2020-03-31
Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT01289457 2020-02-24
Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT01752426 2020-02-24
Pilot Study to Determine Effects of the Btk Inhibitor PCI-32765 on Leukemia Cell Kinetics and Trafficking, Using Heavy Water Labeling in Subjects With CLL and SLL
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00558675 2020-01-22
A Phase I/II Study of Mis-Matched Immune Cells (AlloStim) in Patients With Advanced Hematological Malignancy
Mirror Biologics, Inc.
Phase 1/2 Completed
NCT00048412 2020-01-18
Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H
Baylor College of Medicine
Phase 1/2 Completed
NCT00481871 2020-01-07
Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies
Acrotech Biopharma Inc.
Phase 1/2 Completed
NCT01379209 2019-10-23
Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT)
Regimmune Corporation
Phase 1/2 Completed
NCT01096992 2019-09-25
Fludarabine, Bendamustine, and Rituximab (FBR) for Relapsed Chronic Lymphocytic Leukemia (CLL)
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT01794702 2019-05-30
Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine in Acute Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT03173417 2019-05-20
Safety and Efficacy Evaluation of IM19 CAR-T Cells (IM19CAR-T)
Beijing Immunochina Medical Science & Technology Co., Ltd.
Phase 1/2 Completed
NCT00397579 2019-04-23
DT388IL3 Fusion Protein in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes
University of Texas Southwestern Medical Center
Phase 1/2 Completed
NCT00520130 2019-03-05
Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT00968253 2019-02-27
RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00943319 2019-02-04
Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies
University of Chicago
Phase 1/2 Completed
NCT00295932 2018-11-20
Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT00075010 2018-11-15
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00002831 2018-10-26
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous or Acute Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT01202877 2018-10-16
PKC412 and 5-Azacytidine
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00352001 2018-09-19
Lenalidomide and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndromes
Case Comprehensive Cancer Center
Phase 1/2 Completed
NCT01602952 2018-08-29
Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKI
Il-Yang Pharm. Co., Ltd.
Phase 1/2 Completed
NCT00542971 2018-08-23
Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006)
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT01517035 2018-07-05
Improving Blood Stem Cell Collection and Transplant Procedures
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT01422499 2018-04-11
Vorinostat in Children
National Center for Tumor Diseases, Heidelberg
Phase 1/2 Completed